findmyKOL

Brian Lacy, MD

Enriched profile

Consultant and Professor of Medicine, Division of Gastroenterology and Hepatology · Mayo Clinic

ORCIDNPI
Region🇺🇸 Lebanon, NH · Northeast · United StatesSpecialtyGastroenterologyFocusGastrointestinal motility and disorders+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Brian Lacy is Consultant and Professor of Medicine, Division of Gastroenterology and Hepatology at Mayo Clinic. OpenAlex indexes 367 publications with 17,238 citations (h-index 55); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Gastroenterology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Brian E. Lacy, PHD; MD, is Consultant and Professor of Medicine, Division of Gastroenterology and Hepatology at Mayo Clinic, Jacksonville, FL. The public record shows 367 publications with 17,238 citations (h-index 55), centered on Gastrointestinal motility and disorders, Gastroesophageal reflux and treatments, Helicobacter pylori-related gastroenterology studies. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 13 companies.

  • Most recent indexed publication: 2026 · Therapeutic advances in gastroenterology
  • Top research focus: Gastrointestinal motility and disorders
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 13 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Paresis3 trialsGastroparesis3 trialsIBS / Functional GI2 trialsDyspepsia1 trialDiarrhea1 trialIBD (Crohn's / UC)1 trialCrohn Disease1 trial

Research focus

OpenAlex concept fingerprint
Gastrointestinal motility and disordersGastroesophageal reflux and treatmentsHelicobacter pylori-related gastroenterology studiesCongenital gastrointestinal and neural anomaliesEosinophilic Esophagitis

Drugs & molecules

across trials, industry payments and publications
Ibsrelageneric · TenapanorClinical trialsIndustry payments8Publications1Linzessgeneric · LinaclotideClinical trialsIndustry payments3Publications1XIFAXANgeneric · RifaximinClinical trialsIndustry payments10Publications

Works with

trial sponsors and companies reporting payments
Salix Pharmaceuticals, a division of Bausch Health US, LLCClinical trialsIndustry payments16Ardelyx, Inc.Clinical trialsIndustry payments8Mayo ClinicClinical trials7Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
367publications

Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.

17,238citations

Total citations across indexed works.

55h-index

Hirsch index (OpenAlex). i10-index 142.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
13companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    62.8%
    Proton pump inhibitor32.6%
    Esomeprazole Magnesium100%
    Part D<11 patients
    Serotonin-3 Receptor Antagonist30.2%
    Ondansetron Odt100%
    Part D<11 patients
  • Nervous system

    37.2%
    Other antidepressants37.2%
    Mirtazapine100%
    Part D<11 patients
Where care is delivered (Part B)36.8% facility · 63.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    gastrogirl.com/podcast/what-you-need-to-know-about-ibs

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gastrogirl.com
  • Other

    gi.org/tag/brian-lacy

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gi.org
  • Apple Podcasts

    podcasts.apple.com/us/podcast/medically-refractory-gastroparesis-w-dr-brian-lacy/id1585711586

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Co-Editor-in-Chief

    The American Journal of Gastroenterology

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gi.org
  • Former Editor-in-Chief

    Clinical and Translational Gastroenterology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mayoclinic.org
  • Co-Chairman

    Rome IV Committee on Functional Bowel Disorders (Rome Foundation)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theromefoundation.org
1 more role behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
4 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.